Before the discovery and naming of BBSOAS as a unique syndrome, individuals with NR2F1 mutations were included in autistic, epileptic or other clinical groups, depending on their most prevalent features, leading to poor description of other, apparently unrelated, symptoms. This evidence concerns the gene NR2F1 and Bosch-Boonstra-Schaaf optic atrophy syndrome.